<DOC>
	<DOCNO>NCT00591734</DOCNO>
	<brief_summary>This non-randomized , open label Phase II study compare bevacizumab everolimus treatment metastatic melanoma .</brief_summary>
	<brief_title>RAD001 Plus Bevacizumab Metastatic Melanoma</brief_title>
	<detailed_description>All patient begin treatment dos RAD001 bevacizumab . Patients receive 6 week treatment , follow evaluation . Patients objective response stable disease continue treatment disease progression . During study , patient receive 10 mg RAD001 orally daily 15 mg/kg bevacizumab intravenously ( IV ) every 3 week . Fifty-five patient enrol multi-centered study</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically confirm melanoma . 2 . Unresectable stage IV disease , recurrent disease metastasis . 3 . Measurable disease ( Response Evaluation Criteria Solid Tumors [ RECIST ] ) measurable skin lesion . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . 5 . Life expectancy &gt; =12 week . 6 . Patients allow 02 prior treatment regimen contain chemotherapy and/or immunotherapy ( interferon , interleukin 2 ) . 7 . Women childbearing potential must negative serum pregnancy test 7 day begin treatment . 8 . Absolute neutrophil count ( ANC ) &gt; =1500/µL , platelets &gt; =100,000/µL . 9 . Serum creatinine &lt; =2.0 mg/dL . 10 . Serum bilirubin &lt; =1.5 mg/dL institutional upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 × ULN &lt; 5 × ULN patient document liver metastasis . 1 . Previous treatment bevacizumab antiangiogenesis agent . 2 . Previous treatment mTOR inhibitor . 3 . Drugs substance know inhibitor inducer isoenzyme CYP3A allow . 4 . Treatment investigational agent within 4 week study entry . 5 . Treatment two previous chemotherapy regimen . 6 . Immunization attenuate live vaccine within one week study anytime study treatment period . 7 . Female patient pregnant breastfeeding . 8 . Central nervous system ( CNS ) involvement metastatic melanoma . 9 . CNS disease ( e.g. , seizure control standard medical therapy , history stroke ) . 10 . Any severe and/or uncontrolled medical condition condition could affect participation study : Severely impaired lung function . Uncontrolled diabetes define fast serum glucose &gt; 1.5 ULN , Any acute chronic uncontrolled infection/disorder . Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy . Any acute chronic uncontrolled infection/disorder . Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy . Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . 11 . Acute myocardial infarction ( MI ) previous 6 month . 12 . Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , unstable angina , New York Heart Association [ NYHA ] Class II great congestive heart failure [ CHF ] , serious cardiac arrhythmia require medication ) , &gt; = grade 2 vascular disease . 13 . Clinical history hemoptysis hematemesis . 14 . Clinical evidence history bleed diathesis coagulopathy . 15 . Major surgical procedure , fineneedle aspiration , core biopsy 7 day start treatment . 16 . Patients PEG tube Gtubes . 17 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 18 . Proteinuria screen demonstrate either 1 . Urine protein : creatinine ( UPC ) ratio &gt; = 1.0 screening OR 2 . Urine dipstick proteinuria &gt; = 2+ ( patient discover &gt; =2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; = 1g protein 24 hour eligible ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Everolimus</keyword>
	<keyword>RAD001</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>